Literature DB >> 35440724

Engineered cellular immunotherapies in cancer and beyond.

Amanda V Finck1,2, Tatiana Blanchard3,4, Christopher P Roselle3,4, Giulia Golinelli3,5, Carl H June6.   

Abstract

This year marks the tenth anniversary of cell therapy with chimeric antigen receptor (CAR)-modified T cells for refractory leukemia. The widespread commercial approval of genetically engineered T cells for a variety of blood cancers offers hope for patients with other types of cancer, and the convergence of human genome engineering and cell therapy technology holds great potential for generation of a new class of cellular therapeutics. In this Review, we discuss the goals of cellular immunotherapy in cancer, key challenges facing the field and exciting strategies that are emerging to overcome these obstacles. Finally, we outline how developments in the cancer field are paving the way for cellular immunotherapeutics in other diseases.
© 2022. Springer Nature America, Inc.

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35440724      PMCID： PMC9305718          DOI： 10.1038/s41591-022-01765-8

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   87.241


  146 in total

1.  DEFICIENT GROWTH OF C57BL MARROW CELLS TRANSPLANTED IN F1 HYBRID MICE. ASSOCIATION WITH THE HISTOCOMPATIBILITY-2 LOCUS.

Authors:  G CUDKOWICZ; J H STIMPFLING
Journal:  Immunology       Date:  1964-05       Impact factor: 7.397

2.  Multiparameter immune profiling of operational tolerance in liver transplantation.

Authors:  M Martínez-Llordella; I Puig-Pey; G Orlando; M Ramoni; G Tisone; A Rimola; J Lerut; D Latinne; C Margarit; I Bilbao; S Brouard; M Hernández-Fuentes; J-P Soulillou; A Sánchez-Fueyo
Journal:  Am J Transplant       Date:  2007-02       Impact factor: 8.086

3.  Evidence for a similar or common mechanism for natural killer cell activity and resistance to hemopoietic grafts.

Authors:  R Kiessling; P S Hochman; O Haller; G M Shearer; H Wigzell; G Cudkowicz
Journal:  Eur J Immunol       Date:  1977-09       Impact factor: 5.532

4.  CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.

Authors:  Haydar Frangoul; David Altshuler; M Domenica Cappellini; Yi-Shan Chen; Jennifer Domm; Brenda K Eustace; Juergen Foell; Josu de la Fuente; Stephan Grupp; Rupert Handgretinger; Tony W Ho; Antonis Kattamis; Andrew Kernytsky; Julie Lekstrom-Himes; Amanda M Li; Franco Locatelli; Markus Y Mapara; Mariane de Montalembert; Damiano Rondelli; Akshay Sharma; Sujit Sheth; Sandeep Soni; Martin H Steinberg; Donna Wall; Angela Yen; Selim Corbacioglu
Journal:  N Engl J Med       Date:  2020-12-05       Impact factor: 91.245

5.  Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies.

Authors:  Reuben Benjamin; Charlotte Graham; Deborah Yallop; Agnieszka Jozwik; Oana C Mirci-Danicar; Giovanna Lucchini; Danielle Pinner; Nitin Jain; Hagop Kantarjian; Nicolas Boissel; Marcela V Maus; Matthew J Frigault; André Baruchel; Mohamad Mohty; Athos Gianella-Borradori; Florence Binlich; Svetlana Balandraud; Fabien Vitry; Elisabeth Thomas; Anne Philippe; Sylvain Fouliard; Sandra Dupouy; Ibtissam Marchiq; Maria Almena-Carrasco; Nicolas Ferry; Sylvain Arnould; Cyril Konto; Paul Veys; Waseem Qasim
Journal:  Lancet       Date:  2020-12-12       Impact factor: 79.321

Review 6.  Immune escape mechanisms as a guide for cancer immunotherapy.

Authors:  Gregory L Beatty; Whitney L Gladney
Journal:  Clin Cancer Res       Date:  2014-12-12       Impact factor: 12.531

Review 7.  Immune and Genome Engineering as the Future of Transplantable Tissue.

Authors:  Jennifer Elisseeff; Stephen F Badylak; Jef D Boeke
Journal:  N Engl J Med       Date:  2021-12-23       Impact factor: 91.245

8.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

Authors:  Stephan A Grupp; Michael Kalos; David Barrett; Richard Aplenc; David L Porter; Susan R Rheingold; David T Teachey; Anne Chew; Bernd Hauck; J Fraser Wright; Michael C Milone; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2013-03-25       Impact factor: 91.245

Review 9.  Oncology meets immunology: the cancer-immunity cycle.

Authors:  Daniel S Chen; Ira Mellman
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

10.  Acute rejection of murine bone marrow allografts by natural killer cells and T cells. Differences in kinetics and target antigens recognized.

Authors:  W J Murphy; V Kumar; M Bennett
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307
View more
  3 in total

1.  Probing cell membrane integrity using a histone-targeting protein nanocage displaying precisely positioned fluorophores.

Authors:  Ti Fang; Chaoqun Li; Ao Liang; Hui Zhang; Fan Zhang; Xian-En Zhang; Yi-Yu Yang; Feng Li
Journal:  Nano Res       Date:  2022-09-02       Impact factor: 10.269

Review 2.  MRI techniques for immunotherapy monitoring.

Authors:  Doreen Lau; Pippa G Corrie; Ferdia A Gallagher
Journal:  J Immunother Cancer       Date:  2022-09       Impact factor: 12.469

Review 3.  Adenosine signaling: Optimal target for gastric cancer immunotherapy.

Authors:  Junqing Wang; Linyong Du; Xiangjian Chen
Journal:  Front Immunol       Date:  2022-09-16       Impact factor: 8.786
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.